ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-TERM INPATIENT TREATMENT FOR SCHIZOPHRENIA

Offson M1, Marcus SC2

1Columbia University, New York, NY, USA, 2University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Non-adherence with antipsychotic medications has been implicated as a proximal cause of hospital admission in the community treatment of schizophrenia. OBJECTIVE: To estimate the proportions of short-term inpatient admissions and hospital days for schizophrenia in the United States that are attributable to non-adherence with antipsychotic medications. The 1997 Client/Patient Sample Survey was then used to estimate the national number and length of short-term inpatient admissions for schizophrenia. The 2002 Survey of Mental Health Organizations was used to produce national daily cost estimates of inpatient psychiatric care. The fraction of inpatient short-term admissions attributable to non-adherence was then applied to national estimates of the number and costs of inpatient treatment episodes. RESULTS: Each year in the United States, there are approximately 216,000 short-term inpatient admissions for the treatment of schizophrenia. These admissions include a total of approximately 2.0 million hospital days at a total cost of approximately 1.8 billion dollars. Eliminating non-adherence with antipsychotic medications would lower the number of short-term admissions by approximately 34,300 (15.6%), reduce by approximately 236,000 the number of inpatient treatment days (11.7%), and save approximately 213 million dollars (11.7%) in inpatient care costs. CONCLUSIONS: Non-adherence with antipsychotic medications accounts for a considerable proportion of inpatient treatment costs for schizophrenia. Improving adherence with antipsychotic medications would likely lead to savings by reducing the frequency and duration of inpatient treatment.

COST OF TREATMENT OF HYPERKINETIC DISORDER IN GERMANY

Wehmeier PM1, Rothenberger A2

1Lilly Deutschland, Bad Homburg, Germany; 2University of Göttingen, Göttingen, Germany

OBJECTIVES: To determine the cost of treatment (CoT) associated with Hyperkinetic Disorder (HD) in Germany by age and sex and compare it to the CoT of other childhood disorders. METHODS: Data on the CoT of various childhood disorders (including HD, epilepsy and asthma) were provided by the German Federal Statistical Office for the year 2002. The data had been gathered by the Federal Office from health insurance providers. The data were broken down by diagnosis, age, sex, and the type of resource consumed (inpatient treatment, outpatient treatment, medication). The CoT of HD was then compared to the CoT of epilepsy and asthma. RESULTS: Total treatment costs of HD were €142 million. The highest costs (€128.8 million) were in the age group 0–15 years, where HD is most prevalent, with 0.93% of insured girls and 3.35% of insured boys affected. Costs also reflect this gender difference in prevalence, with €104.6 million incurred by boys and €24.2 million incurred by girls in this age group. Treatment costs can be primarily attributed to inpatient treatment (41.6%), outpatient treatment (38.9%) and medication (5.7%). The treatment cost of HD represents 2.2% of the total CoT in the age group 0–15 years, estimated to be €5,735 million. In this age group, other disorders such as epilepsy (or asthma) incur treatment costs of €199 million (€245 million). For epilepsy (or asthma), inpatient treatment accounts for 56.1% (18.6%), outpatient treatment for 11.1% (11.1%) and medication for 26.9% (59.0%) of CoT. CONCLUSIONS: In Germany in 2002, the CoT of HD was €128.8 million in the age group 0–15 years. The cost of HD was lower than the cost of other common childhood diseases and represents only 2.2% of the total CoT in the age group 0–15 years. Whilst inpatient treatment for HD incurs 41.6% of CoT, medication incurs 5.7%.

ANTIPSYCHOTIC POLYPHARMACY COSTS: A FIVE-STATE MEDICAID STUDY

Valuck RJ1, Morrato EH1, Dodd SL2, Allen RR3

1University of Colorado, Denver, CO, USA, 2Ethicon, Inc, Silesia, MT, USA, 3Peak Statistical Services, Evergreen, CO, USA

OBJECTIVES: State Medicaid programs are scrutinizing atypical antipsychotic prescribing given relatively high costs and use with other psychotropic medications. This study assessed healthcare costs associated with antipsychotic polypharmacy in five state Medicaid programs over six years. METHODS: A retrospective cohort study using Medicaid claims data from California, Oregon, Tennessee, Utah, and Wyoming evaluated 64,411 patients who filled an antipsychotic prescription (1998–2003) and who were eligible 180 days prior to 365 days after the index claim. Analysis was stratified by antipsychotic regimen: polypharmacy (multiple antipsychotic initiation or